Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
2024
2023
2022
2021
2020
2019
-
Dec 12,2024
HuidaGene Therapeutics Announces Landmark Publication in Nature Neuroscience Highlighting HG204’s Potential as First RNA-editing Therapy for MECP2 Duplication Syndrom
Learn More
-
Dec 12,2024
HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient Dosed
Learn More
-
Dec 06,2024
HuidaGene Therapeutics Announced First Patient Dosed in the HERO Clinical Trial of HG204 for MECP2 Duplication Syndrome
Learn More
-
Nov 04,2024
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
Learn More
-
Oct 28,2024
HuidaGene Therapeutics to Attend BIO-Europe Fall 2024 to Expand Global Collaborations in Genome Medicines
Learn More
-
Oct 21,2024
HuidaGene Therapeutics Appoints TJ Cradick, PhD as Chief Technology Officer to Lead Delivery Science and Genome Editing Innovations
Learn More
-
Oct 08,2024
HuidaGene Therapeutics Announces Eleven Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
Learn More
-
Sep 24,2024
HuidaGene Presents Late-Breaking Data at World Muscle Society 2024 Demonstrating HG302 CRISPR/hfCas12Max DNA-Editing Therapy for Duchenne Muscular Dystrophy to Support M.U.S.C.L.E. Clinical Trial
Learn More
-
Sep 09,2024
HuidaGene Therapeutics Announces the Appointment of Dr. Xin Zhang as Chief Operations Officer and Chief Medical Officer to Further Strengthen the Management Team
Learn More